Morgan Stanley Apellis Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 9,752,201 shares of APLS stock, worth $202 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,752,201

Previous 9,626,123 1.31%

Holding current value

$202 Million

Previous $211 Million 19.81%

% of portfolio

0.01%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$16.36 - $23.0 $2.06 Million - $2.9 Million	126,078 Added 1.31%	9,752,201 $169 Million
Q1 2025 May 15, 2025	SELL	$21.87 - $34.63 $24,144 - $38,231	-1,104 Reduced 0.01%	9,626,123 $211 Million
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $163 Million - $221 Million	6,237,442 Added 184.01%	9,627,227 $307 Million
Q3 2024 May 14, 2025	BUY	$28.84 - $41.15 $36.7 Million - $52.3 Million	1,270,888 Added 59.98%	3,389,785 $97.8 Million
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $36.7 Million - $52.3 Million	1,270,888 Added 59.98%	3,389,785 $97.8 Million
Q2 2024 May 14, 2025	SELL	$38.07 - $59.71 $286 Million - $448 Million	-7,508,330 Reduced 77.99%	2,118,897 $81.3 Million
Q2 2024 Oct 17, 2024	BUY	$38.07 - $59.71 $18.3 Million - $28.7 Million	481,279 Added 29.39%	2,118,897 $81.3 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $18.3 Million - $28.7 Million	481,279 Added 29.39%	2,118,897 $81.3 Million
Q1 2024 Oct 17, 2024	SELL	$55.39 - $72.47 $26.7 Million - $34.9 Million	-481,279 Reduced 22.71%	1,637,618 $96.3 Million
Q1 2024 Aug 16, 2024	SELL	$55.39 - $72.47 $80.8 Million - $106 Million	-1,459,523 Reduced 47.12%	1,637,618 $96.3 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $80.8 Million - $106 Million	-1,459,523 Reduced 47.12%	1,637,618 $96.3 Million
Q4 2023 Aug 16, 2024	BUY	$37.14 - $64.82 $36.3 Million - $63.4 Million	978,244 Added 46.17%	3,097,141 $185 Million
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $55.3 Million - $96.5 Million	1,488,145 Added 92.49%	3,097,141 $185 Million
Q3 2023 Nov 15, 2023	BUY	$23.65 - $89.22 $20.2 Million - $76 Million	852,331 Added 112.64%	1,608,996 $61.2 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $291,614 - $354,857	3,803 Added 0.51%	756,665 $68.9 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $21.1 Million - $30.3 Million	452,979 Added 151.05%	752,862 $49.7 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $3.31 Million - $4.68 Million	76,607 Added 34.31%	299,883 $15.5 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $10.3 Million - $16 Million	-229,744 Reduced 50.71%	223,276 $15.3 Million
Q2 2022 Oct 27, 2022	BUY	$35.07 - $59.21 $7 Million - $11.8 Million	199,631 Added 78.78%	453,020 $20.5 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $7 Million - $11.8 Million	199,631 Added 78.78%	453,020 $20.5 Million
Q1 2022 Oct 27, 2022	SELL	$35.46 - $54.12 $7.08 Million - $10.8 Million	-199,631 Reduced 44.07%	253,389 $12.9 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $6.59 Million - $10.1 Million	185,730 Added 274.51%	253,389 $12.9 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $3.37 Million - $5.39 Million	-109,637 Reduced 61.84%	67,659 $3.2 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $5.57 Million - $12.4 Million	177,296 New	177,296 $5.84 Million

Others Institutions Holding APLS

# of Institutions

302

Shares Held

134M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.27B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account